T icagrelor is an oral antiplatelet agent that binds reversibly to the P2Y12 receptor without the requirement for metabolic activation. 1 The Food and Drug Administration and the European Medicines Agency approved ticagrelor in 2011 and 2010, respectively, for the treatment of patients with an acute coronary syndrome (ACS). Data from pivotal randomized clinical trials demonstrated a reduction in death, myocardial infarction, or stroke compared with clopidogrel, 2 resulting in class IB indication for the treatment of patients with NSTE-ACS or ST-segment-elevation myocardial infarction in American Heart Association/American College of Cardiology and European Society of Cardiology guidelines of 2016. Furthermore, although the absence of randomized data is notable, there is consensus that the use of ticagrelor may also be considered in selected stable coronary artery disease patients in whom the concerns around the ischemic risk prevail. 3 The clinical benefit of ticagrelor, however, has been associated with the more frequent occurrence of adverse effects. 4, 5 As a result, the risk for premature drug discontinuation was 9% to 19.0% higher among ticagrelor-treated patients compared with clopidogrel in phase III trials, Premature Ticagrelor Discontinuation mainly related to a higher occurrence of nonprocedurerelated bleeding and dyspnea. 2, 6, 7 Patients undergoing treatment outside of randomized controlled trials are reportedly less compliant with prescribed medications and carry more comorbidities, a circumstance that is associated with a higher risk for drug adverse effects (eg, bleeding) and interactions as compared with patients included in randomized controlled trials. 8, 9 Nonadherence is a recognized and common medical problem associated with impaired long-term outcomes and an increased risk of recurrent ischemic events, including stent thrombosis after drugeluting stent implantation. 10, 11 Although ticagrelor discontinuation in real-world setting has been reported, 12 underlying reasons, frequencies, and clinical implications of different P2Y12 inhibitor switch modalities have not been investigated. Against this background, we sought to assess premature ticagrelor discontinuation in an allcomer cohort of patients undergoing percutaneous coronary intervention (PCI) with primarily second-generation drugeluting stents.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
As of January 2009, all patients undergoing PCI at Bern University Hospital, Switzerland, have been prospectively entered into the Bern PCI Registry (NCT02241291). 13 The present analysis included all consecutive patients discharged on ticagrelor who were enrolled between November 2011, when ticagrelor was introduced in our center, and June 2014. Exclusion criteria were treatment by balloon angioplasty without stent placement and enrollment in a new clinical trial before 1-year follow-up. There were no other exclusion criteria, and all patients provided written informed consent as part of a standard procedure. Demographic and clinical characteristics, procedural information, in-hospital outcomes, and 1-year follow-up data were systematically and prospectively collected. Ticagrelor adherence was assessed by a questionnaire, 14 and a review of all medical reports obtained in the context of clinical events or changes in antiplatelet therapy. Reasons, duration, and date of ticagrelor cessation were recorded, and in case ticagrelor was replaced by a different P2Y12 inhibitor, replacement therapy and initiation date were recorded as well. This prospective registry was approved by the institutional ethics committee, and all patients provided written informed consent.
Procedures
PCI was performed in accordance with current clinical practice guidelines. 15 Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor was initiated before, at the time, or immediately after the PCI procedure. Aspirin at a dose of 100 mg once daily was continued indefinitely, and the recommended duration of DAPT was 12 months. Institutional guidelines recommended the use of clopidogrel in stable coronary artery disease patients with the option of using potent P2Y12 inhibitors in patients in whom the concerns on the ischemic risk prevailed. Patients with ACS were generally recommended to be treated with a potent P2Y12 inhibitor under consideration of the individual bleeding and ischemic risk. No preference was given with regards to the selection of the type of potent P2Y12 inhibitor.
Patient Follow-Up
Patients were systematically followed throughout 1 year to assess major adverse cardiac and cerebrovascular events and adherence to medical treatment. Survival data were obtained from hospital records and municipal civil registries. A health questionnaire was sent to all living patients with questions on rehospitalization, adverse effects, and adherence related to P2Y12 therapy, followed by telephone contact in case of missing response. General practitioners, referring cardiologists, and patients were contacted as necessary for additional information. For patients who experienced cardiovascular events or change in ticagrelor therapy, external medical records, discharge letters, and coronary angiography documentation were systematically collected and reviewed.
Clinical End Points and Definitions
A clinical event committee consisting of 2 cardiologists (and a third referee in case of disagreement) adjudicated all events using original source documents. Definitions are provided in the Data Supplement. Ticagrelor cessation before the recommended 12-month treatment regimen was categorized according to the international expert consensus on switching platelet P2Y12 receptor-inhibiting therapies 16 : (1) change, when ticagrelor was replaced by prasugrel; (2) de-escalation, when ticagrelor was replaced by clopidogrel; and (3) premature discontinuation, when ticagrelor was discontinued but not replaced by any P2Y12 inhibitor. The terminology cessation was used to refer to any mode of ticagrelor discontinuation (change, de-escalation, and premature discontinuation). In case dyspnea was the adverse effect leading to treatment cessation, a second follow-up via phone was performed to investigate whether the dyspnea symptoms dissolved as a consequence of treatment cessation.
Statistical Analysis
Continuous variables are summarized as mean±SD and categorical (including binary) ones as count (%) . P values for between-group comparisons are based on t tests, Fisher exact tests, and χ 2 square tests as appropriate. Lesion level analysis was adjusted for multiple lesions per patient using a random intercept indicating the patient in a mixed model approach. Continuous variables were analyzed using linear mixed models, binary variables using binary logistic regression mixed models, categorical variables using multinomial logistic regression mixed models, and count variables using Poisson regression mixed models. Predictors for any mode of premature ticagrelor
WHAT IS KNOWN
• Ticagrelor improved cardiovascular outcomes among patients experiencing an acute coronary syndrome as compared with clopidogrel but was associated with a higher rate of premature drug discontinuation in randomized controlled trials.
WHAT THE STUDY ADDS
• This study showed that in real-world clinical practice, premature ticagrelor cessation occurs in 1 of 6 patients whereby the majority de-escalated to clopidogrel while ticagrelor discontinuation or change to prasugrel was observed less frequently.
• Premature ticagrelor cessation was primarily related to adverse effects, among which bleeding and dyspnea were the most frequent.
• In the present real-world observational study, neither of the different modes of premature ticagrelor cessation was associated with worse cardiovascular outcomes. Premature Ticagrelor Discontinuation cessation are modeled using bivariable logistic regression models, and those predictors that showed a significant relationship are used in a multivariable model. Nonparametric estimates of the cumulative incidence functions under a competing risk approach are used to depict the time to each cessation event. Clinical outcomes were analyzed using Cox models with a time-varying covariate depicting the period of ticagrelor cessation defined as no ticagrelor cessation versus change to prasugrel versus de-escalation to clopidogrel versus premature ticagrelor discontinuation without replacement using a robust variance estimator. To perform these analyses, follow-up time of patients with a premature ticagrelor cessation was split into these periods. The no ticagrelor cessation constituted the reference period and patients who did not discontinue contributed to this period. The time to first clinical event within each period was analyzed, and a clustering effect was included to account for patients contributing in both periods. An additional analysis, in which we grouped together the different ticagrelor cessation modes as any type of ticagrelor cessation versus no ticagrelor cessation, was performed. Patients who were lost to follow-up (n=69; 5.4%) were included in the analysis for clinical end points and censored at the last time there was knowledge they were alive using the DAPT status at this time point for group categorization. Analyses were performed in Stata version 14.2 and R version 3.3.1.
Results
Of 4837 consecutive patients prospectively enrolled into the Bern PCI Registry between November 2011 and June 2014, 1278 patients (26.5%) were discharged on ticagrelor and met the criteria for inclusion (Figure 1 ), of which 1209 patients completed follow-up (Table I in the Data Supplement). NSTE-ACS (n=659; 52%) represented the most frequent clinical indication followed by ST-segment-elevation myocardial infarction (n=273; 21%) and stable coronary artery disease (n=172; 14%) and silent ischemia (n=71; 6%). The vast majority of patients underwent PCI with the use of second generation drug-eluting stent (99%) whereas only few (n=23; 1%) received bare-metal stents. Table 1 presents baseline and procedural characteristics at the time of enrollment for patients who continued ticagrelor therapy as recommended for 1 year versus patients who prematurely stopped ticagrelor therapy according to different modes of cessation. Compared with patients who were adherent to ticagrelor therapy, patients who changed to prasugrel had more frequently a previous PCI and a previous myocardial infarction. Patients who de-escalated to clopidogrel compared with patients adherent to ticagrelor were more frequently female, less frequently smokers, suffered more frequently from renal impairment, and had more frequently a previous PCI. Patients who prematurely discontinued ticagrelor therapy were older and suffered more frequently from renal impairment compared with patients adherent to ticagrelor therapy.
Baseline and Procedural Characteristics

Adherence to Ticagrelor
Reasons leading to premature ticagrelor cessation are summarized in Table 2 and were in descending order: adverse effects (49%), initiation of oral anticoagulation (19%), unspecified preference by the general practitioner (10%), surgery or medical interventions (5%), and financial reasons (2%).
Adverse effects leading to ticagrelor cessation are shown in Figure 2 . Bleeding (41%), dyspnea (29%), and gastrointestinal symptoms (18%) were responsible for 88% of adverse effects leading to premature ticagrelor cessation. Most bleeding episodes leading to ticagrelor cessation The time course of ticagrelor cessation by different modes is presented in Figure 3 . Within 1 year, 9.1% of patients deescalated to clopidogrel, 2.5% of patients changed to prasugrel, and 5.2% discontinued ticagrelor therapy without replacement. The median time to premature cessation because of an adverse event not related to bleeding was 42 days (interquartile range, 20-103) and 61 days (interquartile range: 25-157) for bleeding-related cessation.
Ticagrelor-Induced Dyspnea
Cessation because of dyspnea occurred among 31 patients (2.4%), of which 24 patients (77%) reported an immediate amelioration while the remaining 7 patients (23%) did not report any improvement. Subsequent clinical examinations revealed a pulmonary or cardiac diagnosis in 5 of these patients, and no somatic explanation in the remaining 2 patients. The median duration until dyspnea-related discontinuation was 36 days (interquartile range: 10-95). Table II in the Data Supplement shows baseline and procedural characteristics of patients with versus without definite ticagrelor-related dyspnea. Patients with definite ticagrelor-related dyspnea were more often treated for stable angina and had more frequently a previous PCI and previous myocardial infarction. Table 3 shows the estimated risk associated with any type of ticagrelor cessation, and Table III in the Data Supplement shows the primary composite end point in relation to person years stratified according to different modes of ticagrelor cessation. There were no differences on the primary composite end point, including cardiac death, myocardial infarction, or stroke, at 1 year between patients who were adherent to ticagrelor therapy throughout 1 year and patients with any type of ticagrelor cessation (hazard ratio, 0.73; 95% CI, 0.40-1.32; P=0.29). , small vessel was defined as minimal stent diameter ≤2.5 mm, and long lesions were defined as total stent length ≥28 mm. Depicted are means with SDs (P values from independent samples t test) and categorical variables as actual numbers and percentages (P values from Fisher exact test and χ 2 square tests for >2 responses). BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVI, cerebrovascular insult; DES, drug-eluting stent; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction.
Clinical Outcomes
*Lesion-level analysis were adjusted for multiple lesions per patient. 11, [17] [18] [19] [20] Approximately 50% of ticagrelor cessations were the result of ticagrelor-specific adverse effects (ie, most frequently bleeding, dyspnea, and gastrointestinal symptoms), and the remainder included various clinical scenarios, such as the initiation of oral anticoagulation, unspecified preference of the treating physician, or medical interventions. In keeping with observations obtained from PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction) with the majority of patients discontinuing ticagrelor early after treatment onset, 21 >60% of patients discontinued ticagrelor within the first 90 days. Of note, two third of patients who discontinued ticagrelor changed to either clopidogrel or prasugrel, resulting in an overall high adherence to any DAPT throughout 1 year (>90%), suggesting that the availability of multiple oral P2Y12 inhibitors with differing potencies and side effect profile might increase overall adherence to DAPT treatment recommendation. Potentially in relation to this observation, we did not identify an increased ischemic risk associated with premature ticagrelor cessation.
De-escalation from ticagrelor to clopidogrel represented the most frequent switch in P2Y12 inhibitor therapy occurring among 10% of patients and was not associated with an impaired cardiovascular prognosis. These findings are in line with 2 recent randomized controlled trials that assessed an early de-escalation to clopidogrel therapy 2 or 4 weeks after discharge, respectively, and found no increase in ischemic events. 22, 23 However, the TOPIC trial (Timing of Platelet Inhibition After Acute Coronary Syndrome) requires careful interpretation in view of its sample size, 22 and the TROPICAL-ACS trial (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes) used platelet function testing to guide de-escalation from prasugrel to clopidogrel whereby 40% of patients were re-escalated to prasugrel after high on clopidogrel platelet reactivity was identified. 23 Conversely, the SCOPE registry (Switching From Clopidogrel to New Oral Antiplatelet Agents During Percutaneous Coronary Intervention) findings 12 suggested that patients who de-escalated within the first month after the index event in patients with ACS had a higher rate of ischemic events at 1-month follow-up. Platelet reactivity clearly increases after de-escalation, 24 and potential drug-drug interaction is currently being investigated (SWAP-4 [Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease]; ClinicalTrials.gov. NCT02287909). Regarding deescalation, current guidelines recommend to use a clopidogrel loading dose of 600 mg because of the fast offset of action with ticagrelor, and a maintenance dose of clopidogrel when bleeding represents the rational to de-escalate. 16 Bleeding-related cessation was higher in the present observational study when compared with the PLATO trial (Platelet Inhibition and Patient Outcomes) (PLATO: 2.4% versus Bern PCI Registry: 3.4%) even though the overall occurrence of Thrombolysis in Myocardial Infarction major bleeding was higher in the ticagrelor arm of the PLATO trial (PLATO: 7.9% versus Bern PCI Registry: 1.7%), indicating that minor bleedings in routine clinical practice may more likely lead to treatment cessation as compared with a clinical trial environment. Similarly, when compared with clopidogrel treated patients in previous DAPT registries, 17, 19 bleeding-related cessation was reported twice as likely in the Dyspnea is a well-known side effect of ticagrelor, which mostly occurs early after treatment onset, is of temporary nature and does not manifest with an impaired pulmonary function. 26, 27 Rates of cessation because of dyspnea amounted to 5% in phase III trials enrolling stable patients (ie, patients with peripheral artery disease or prior myocardial infarction) 6, 28 and 0.9% among patients with ACS in the PLATO trial, 2 possibly because minor symptoms are better tolerated or may be attributed to other causes than drug related effects in the early phase of an ACS. 29 This hypothesis is further corroborated in the present analysis in which dyspnea-related cessation was low among patients with ACS (1.2%) and higher among patients with stable coronary artery disease treated offlabel (4.8%). Interestingly, among 31 patients discontinuing ticagrelor because of dyspnea, 7 patients (22%) did not report any improvement thereafter. Subsequent examinations showed a cardiac or pulmonary cause for dyspnea sensation, which emphasizes the diagnostic challenge of dyspnea in PCI patients and highlights the possibility of re-establishing ticagrelor in case the cessation does not result in dyspnea resolution.
The PLATO trial reported similar rates of cessations related to adverse effects (excluding bleedings) in clopidogrel-and ticagrelor-treated patients (5.0% for both) which is in line with our results (4.9%). Notably, this rate is >3-fold higher as compared with side effect-related cessations observed among >11 000 NSTE-ACS and ST-segment-elevation myocardial infarction patients in the TRANSLATE registry (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) treated with either clopidogrel or prasugrel (1.8% for both). 17 Reasons for this discrepancy remain unclear and cannot be adequately assessed within our registry because of the methodological limitation of leaving the choice of P2Y12 inhibitor to the discretion of the treating physician. Side effects also represented the most common reason to change P2Y12 therapy to prasugrel. Although clinical data assessing the safety or efficacy of such an approach are currently lacking, changing from ticagrelor to prasugrel resulted in an increase in high platelet reactivity rates 30 whereas, intriguingly, a change from prasugrel to ticagrelor was not associated with any interaction. 31 On this basis, current guidelines recommend to change from ticagrelor to prasugrel with a 60-mg loading dose and to switch 24 hours after the last maintenance dose of ticagrelor to limit the increase in platelet reactivity. 16 Although several previous registries reported impaired outcomes associated with DAPT nonadherence, 11, 20 we did not identify an increased risk of major adverse cardiovascular events after any modality of ticagrelor cessation. There are several potential explanations for this observation. First, the effect of DAPT nonadherence on ischemic events in previous trials was mainly related to the early (ie, 30 days) time period but no longer present thereafter. 11 During this 30-day period, we observed only 6 patients (0.5%) who completely stopped P2Y12 therapy, and none of them experienced an ischemic event within this time frame. Second, almost half of the premature ticagrelor cessations were physician guided-a scenario that protected from ischemic events in previous trials. Third, in comparison to previous observations, late stent thrombosis rate was low (0.2%), likely reflecting ongoing refinements in stent technology. Fourth, patients who discontinued ticagrelor therapy were characterized by a higher bleeding risk. Finally, the sample size and the observed event rates may be too low to detect an association with ischemic events.
Limitations
The present study has several limitations. First, differences in treatment adherence were noted across different countries which enrolled patients within the same study 32 whereas the present investigation represents observations from a single large tertiary center in Switzerland. Second, comparison with previous DAPT adherence trials is hampered by the fact that 3 oral P2Y12 inhibitors were available during the present study. Physicians in previous trials were faced with the options discontinuation versus no discontinuation (with or without temporary interruption) of clopidogrel while currently it is possible to de-escalate treatment to clopidogrel in high bleeding risk settings or to change to prasugrel. Third, the present Depicted are hazard ratios and 95% confidence intervals (P values from Cox models with time-varying covariate the ticagrelor cessation status: no ticagrelor discontinuation [reference] vs premature ticagrelor discontinuation), including the use of a robust variance estimator. Disc. indicates discontinuation; and MI, myocardial infarction. Premature Ticagrelor Discontinuation study design, which left the choice of P2Y12 inhibitor to the physician's discretion, likely affected the observed adherence rate to ticagrelor. Fourth, in view of the primary method of follow-up via a prespecified questionnaire, recall bias could have occurred. To minimize this, however, our registry required adjudication of all ticagrelor cessations by use of any available source documentation, including clinical visits, hospital admissions or notes, and prescriptions from physicians. In addition, medication status before and after all clinical events was carefully assessed. In case a patient died, close relatives, general practitioners, and responsibilities in nursing homes were contacted to obtain reliable information.
Conclusions
Premature ticagrelor cessation in routine clinical practice occurred in 17% of patients and was primarily related to adverse effects among which bleeding and dyspnea were the most frequent. Although ticagrelor cessation was not associated with adverse cardiovascular outcomes, this finding requires careful interpretation in view of the modest sample size.
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